DT-7012

Phase 2Small molecule

DDomain Therapeutics Australia Pty Ltd

DT-7012 is one of 25 small molecule programs targeting Cutaneous T-cell lymphoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cutaneous T-Cell LymphomaNot yet recruiting

Immune Checkpoint InhibitorRecruiting

Cutaneous T-Cell LymphomaPhase 1

Not yet recruiting

Immune Checkpoint InhibitorPhase 2

Recruiting

Competition

Competitive Landscape

19 competitors in Cutaneous T-Cell Lymphoma

#DrugCompanyPhaseTrials

Adcetris

Pfizer

Approved

4 2

Trexall

Jazz Pharmaceuticals

Approved

2 3

Targretin

BBausch Health Americas, Inc.

Approved

6 4

Tecfidera

Adriamycin

Venclexta

Revlimid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

1 8

Beleodaq

AAcrotech Biopharma Inc.

Approved

—9

Aldara

BBausch Health Americas, Inc.

Approved

—10

Rapamune

PPrism Pharmaceuticals

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1/2Recruiting

Immune Checkpoint Inhibitor

NCT06819735

Q3 2028

Phase 1Not yet recruiting

Cutaneous T-Cell Lymphoma

NCT07213882

Q4 2031

Phase 2Not yet recruiting

Undifferentiated Pleomorphic Sarcoma (UPS)

NCT07802652

Clinical

Trials by Indication[1]

Cutaneous T-cell lymphoma1 trial

A Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation Clinical Trial of Domain Therapeutics' Anti-CCR8 Monoclonal Antibody (DT-7012) in Patients With Relapsed or Refractory Cutaneous T-cell Lymphomas (CTCL)

Not yet recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 1·NCT07213882·30 enrolled

Immune Checkpoint Inhibitor1 trial

Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors

Recruiting·DDomain Therapeutics Australia Pty Ltd·Phase 1/2·NCT06819735·125 enrolled

Undifferentiated Pleomorphic Sarcoma (UPS)1 trial

A Randomized Phase II Study of Doxorubicin With or Without DT-7012 in Advanced Soft Tissue Sarcoma

Not yet recruiting·GGustave Roussy, Cancer Campus, Grand Paris·Phase 2·NCT07802652·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for DT-7012. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DT-7012 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DT-7012. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Domain Therapeutics Australia Pty Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: DDomain Therapeutics Australia Pty Ltd

DT-7012

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q3 2028

Q4 2031

Trials by Indication[1]

Cutaneous T-cell lymphoma1 trial

Immune Checkpoint Inhibitor1 trial

Undifferentiated Pleomorphic Sarcoma (UPS)1 trial

References

Drug Info

Quick Facts

Related News